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Understanding how combinations of HLA and KIR 
genes inﬂuence disease
 
Sumati Rajagopalan and Eric O. Long
 
Combinations of HLA and killer cell immunoglobulin–like receptor (KIR) genes 
have been associated with diseases as diverse as autoimmunity, viral 
infections, reproductive failure, and now cancer. Much as early observations of 
disease associations with HLA polymorphism preceded a detailed knowledge of 
HLA recognition by T cell receptors, the recently reported disease associations 
with HLA–KIR gene combinations beg for a better understanding of the 
underlying mechanisms.
 
KIRs and ligands
 
Natural killer (NK) cells are regulated
in part by inhibitory receptors that rec-
ognize MHC class I molecules on normal
cells. In humans, inhibitory receptors
that recognize classical MHC class I mol-
ecules (HLA-A, HLA-B, and HLA-C)
belong to the KIR family. KIRs are a
family of 
 
 
 
15 closely linked genes lo-
cated on chromosome 19q13.4, which
encode both inhibitory and activating
receptors that are expressed by NK cells
and by subsets of 
 
  
 
 
 
 T cells and mem-
ory and effector 
 
  
 
 
 
 T cells. The reason
for KIR diversity and the contribution
of individual KIRs to signaling in NK
cells and T cells are not fully under-
stood, but their importance has been
underscored by several recent genetic
studies, including one in this issue (1),
which have linked combinations of KIR
and HLA genes with the outcome of
various diseases (Table I) (2–8). Associa-
tions with different HLA–KIR combi-
nations, involving activating KIRs or
inhibitory KIRs to different extents, have
been described. The data suggest that dis-
ease can be modified by specific KIR–
ligand interactions, rather than by global
responsiveness of NK cells or T cells.
KIRs contain either two or three
immunoglobulin-like domains with ei-
ther long (2DL, 3DL) or short (2DS,
3DS) cytoplasmic tails (Table II) (9).
Long-tailed receptors carry one or two
immunoreceptor tyrosine-based inhibi-
tion motifs (ITIMs), which contribute
to inhibitory signaling. Short-tailed re-
ceptors have a lysine residue in their
transmembrane domain that is required
for pairing with the immunoreceptor
tyrosine-based activation motif (ITAM)–
containing adaptor DAP12. Several in-
hibitory KIRs have well-defined MHC
class I ligands (Table II) (10, 11). The
ligands for activating KIRs, however,
have been more elusive. Despite high
sequence similarity with some of the
inhibitory receptors, activating KIRs
show either weak or undetectable bind-
ing to HLA class I (12–14).
 
KIR genotypes and disease
 
A striking feature of KIR genes is their
lack of conservation among species and
their rapid evolution, which cannot be
accounted for solely by divergence in
HLA class I molecules (15). If KIR
gene evolution were pathogen driven,
some of the diversity would be expected
to correlate with resistance or sensitivity
to certain infectious diseases. Indeed,
several genetic studies of viral infection
have revealed an influence of HLA–
KIR gene interactions on disease out-
come (Table I). An interaction between
 
KIR3DS1
 
 and a subset of 
 
HLA-Bw4
 
alleles—those with Ile at position 80—
is associated with delayed progression
to AIDS in HIV-infected individuals
(2). In the case of hepatitis C virus
(HCV) infection, homozygosity of both
 
HLA-C1
 
 and 
 
KIR2DL3
 
 is associated
with resolution of infection (4). A hy-
pothesis proposed to explain the latter
finding is that KIR2DL3 binds HLA-C
with lower affinity than KIR2DL1 and
KIR2DL2 receptors, thus reducing NK
cell inhibition and favoring resolution
of the infection. However, direct affinity
measurements have not revealed a dif-
ference between KIR2DL binding to
their respective HLA-C ligands (Table
II). The report in this issue (1) reveals a
predisposition to human papilloma virus
(HPV)–induced cervical cancer with
HLA–KIR gene combinations that seem
to favor NK cell activation. In contrast
to correlations seen with HIV and HCV
infections, disease progression toward
cervical neoplasia seems enhanced by an
increase in activation signals.
Combinations of certain HLA–KIR
genotypes have also been linked with
susceptibility to autoimmune diseases.
Thus, a combination of 
 
KIR2DS1
 
 and/
or 
 
KIR2DS2
 
 coupled with homozy-
gosity of an HLA-C group favors suscep-
tibility to psoriatic arthritis (5). Suscepti-
bility could be due to reduced NK cell
inhibition, as individuals homozygous for
 
HLA-C1
 
 lack a ligand for KIR2DL2 and
KIR2DL3, and those homozygous for
 
HLA-C2
 
 lack a ligand for KIR2DL1.
Similarly, 
 
KIR2DS2
 
 combined with
 
HLA-C1
 
 in the absence of 
 
HLA-C2
 
and 
 
HLA-Bw4
 
 is associated with in-
creased susceptibility to type I diabetes
(3). Likewise, 
 
KIR2DS1
 
 in combina-
tion with 
 
HLA-Cw
 
*
 
06
 
 is a risk factor
for psoriasis vulgaris (7). HLA–KIR
combinations that favor NK cell or T
cell activation may have been selected
to improve resistance to viruses and to
malignancy (8), despite an associated risk
of developing autoimmunity (Table I).
HLA–KIR gene combinations that
seem to favor NK cell inhibition have
also been associated with preeclampsia
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(6), a potentially fatal condition caused
by incomplete remodeling of spiral ar-
teries in maternal decidua and by high
blood pressure during pregnancy. Vas-
cular remodeling is required to provide
the fetus with an adequate blood sup-
ply. Susceptibility is associated with the
combination of HLA-C2 on fetal tro-
phoblast cells and KIR2DL1 on mater-
nal cells, and is further increased by the
absence of activating 
 
KIR2DS
 
 genes (6).
A potential explanation of these findings
is that KIR2DL1 confers a strong inhi-
bition, compared with KIR2DL2 or
KIR2DL3, which prevents activation
of NK cells during interaction with fe-
tal trophoblast cells in the decidua. In
this context, activation of NK cells is
thought to facilitate implantation through
cytokine production.
 
Potential mechanisms
 
NK cells are important regulators of
immune responses. Their function ex-
tends  beyond killing of infected or
transformed cells. Interactions with den-
dritic cells, macrophages, and fetal tro-
phoblast cells can regulate NK cell
activity by influencing cytokine pro-
duction, cytotoxicity, and stimulation
of T helper-1 responses. Stimulation of
NK cells can be beneficial during vi-
rus infections, malignant transforma-
tion, and pregnancy, but deleterious in
the context of autoimmunity or neo-
plastic transformation. The latter may
be provoked by chronic inflammation,
which is a known risk factor in devel-
oping cancer during persistent infec-
tions. HPV establishes latency by pre-
venting NK-mediated lysis of infected
cells (16). It would be interesting to test
if HPV infection provokes a proin-
flammatory cytokine response from
NK cells in the absence of cytotoxicity,
thereby favoring neoplasia. A simple
interpretation of the observed genetic
correlations might suggest that KIR3DS1
stimulates cytokine production by NK
cells, which contributes to inflamma-
tion. However, a few key aspects of
NK cell biology need to be consid-
ered when interpreting such genetic
analyses.
 
A complex repertoire of polymorphic KIRs
 
Understanding the basis for the ob-
served genetic associations is compli-
cated by the large repertoire of recep-
tors used by NK cells to interpret
their environment. There is extensive
polymorphism among KIR haplotypes,
which differ not only in nucleotide
sequence but also in gene content
(17). Different haplotypes carry differ-
ent numbers of KIR genes, some with
few or no activating KIRs (A haplo-
types) and others with several activat-
ing KIRs (B haplotypes). In addition,
each NK cell carries its own repertoire
of KIRs. Individuals with several acti-
vating KIR genes simply have a higher
probability of expressing activating
KIRs on any given NK cell than indi-
viduals who have fewer activating
KIRs. Therefore, a given disease asso-
ciation with HLA–KIR gene combina-
tions, for instance, an activating KIR
and its HLA ligand, cannot be inter-
preted simply as an overall enhance-
ment in NK cell activation signals.
Furthermore, a selection process (the
mechanism of which is unknown) is in
place to ensure that each NK cell has at
least one inhibitory receptor specific
for a self HLA class I molecule. If, for
instance, an NK cell lacks all of the
major inhibitory KIRs, it will express
the heterodimeric inhibitory receptor
CD94–NKG2A (18), which binds to
the nonclassical HLA-E. A new inhibi-
tory receptor–ligand combination, which
is independent of MHC class I, has re-
cently been discovered on mouse NK
cells: binding of NKR-P1 receptors to
the widely expressed C-type lectin Clr-b
inhibits NK cell activation (19, 20). A
similar HLA-independent regulation
could also operate in human NK cells.
Therefore, it is not clear that KIR hap-
lotypes carrying several activating KIRs
would necessarily result in NK cells
that are more easily activated, as the
expression of activating KIRs should
be compensated by the expression of
inhibitory receptors.
 
Elusive role of activating KIR
 
Activating KIRs are completely dis-
pensable, as KIR haplotypes lacking
all functional 2DS and 3DS genes are
common (21). In addition, all individ-
uals have a subset of NK cells that are
completely devoid of activating KIRs.
As activating and inhibitory KIRs are
not coordinately expressed, it is un-
likely that activating KIRs contribute
 
Table I.
 
Disease associations with combinations of KIR and HLA genes
 
Disease KIR HLA Disease progression Proposed contribution by KIRs Reference
 
AIDS
 
3DS1
3DS1
 
 homozygous
 
HLA-Bw4
 
Ile80
 
No 
 
HLA-Bw4
 
Ile80
 
Decreased
Increased
Less inhibition
More inhibition
(2)
HCV infection
 
2DL3
 
 homozygous
 
HLA-C1
 
 homozygous Decreased Less inhibition (4)
Cervical neoplasia 
(HPV-induced)
 
3DS1
 
No 
 
3DS1
HLA-C1
 
 homozygous 
and no 
 
HLA-Bw4
HLA-C2
 
 and/or 
 
HLA-Bw4
 
Increased
Decreased
Less inhibition
More inhibition
(1)
Malignant melanoma
 
2DL2
 
 and/or 
 
2DL3 HLA-C1
 
Increased More inhibition (8)
Psoriatic arthritis
 
2DS1
 
 and/or 
 
2DS2
HLA-C1
 
 homozygous or
 
HLA-C2
 
 homozygous
Increased Less inhibition (5)
Type I diabetes
 
2DS2 HLA-C1
 
 and no 
 
HLA-C2
 
, 
no 
 
HLA-Bw4
 
Increased Less inhibition (3)
Preeclampsia
 
2DL1
 
 with fewer
 
2DS
 
 (mother)
 
HLA-C2
 
 (fetus) Increased More inhibition (6)
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to the function of inhibitory KIRs.
The ligand specificity of activating KIRs
is unclear. KIR2DS1 and KIR2DS2
may bind HLA-C with a lower affinity
than that of closely related inhibitory
KIRs (12, 14), but it is also possible
that alternate ligands exist, such as
the non-HLA ligand for KIR2DS4 on
melanoma cells (22). In the mouse
Ly49 receptor family, which is struc-
turally distinct from but functionally
equivalent to human KIRs, the activat-
ing Ly49H and the inhibitory Ly49I
receptors bind to the m157 protein of
mouse cytomegalovirus (23, 24), sug-
gesting that KIRs may also have viral
protein ligands. It is essential to deter-
mine the ligand specificity of activating
KIRs in order to interpret genetic cor-
relations with diseases. It is also possible
that activating KIRs have ligand-inde-
pendent functions.
Expression of activating KIRs on
subsets of T cells could contribute to
some of the associations seen in the
genetic studies. It is conceivable that ac-
tivating KIRs may synergize with TCR-
mediated signals to cause aberrant
immune activation and autoimmune
reactions. KIR2DS2, which is expressed
by a large percentage of CD4
 
 
 
CD28
 
–
 
T cells in rheumatoid arthritis patients
with vascular complications, is also a
genetic risk factor for this disease (25).
Even though T cells lack DAP12, ex-
pression of KIR2DS2 costimulated TCR
signals which, although suboptimal, re-
sulted in cytokine secretion (26).
 
Peptide selectivity in recognition of 
HLA by KIR
 
Side chains that extend out of the
peptide-binding groove of HLA-B and
HLA-C molecules can interfere with
binding of inhibitory KIRs (10). Al-
though peptide-specific recognition by
activating KIRs has been proposed as a
potential mechanism to activate NK
cells during infections, it is extremely
unlikely that self/nonself discrimina-
tion is achieved by KIRs, primarily
because each KIR binds to different
HLA-B or HLA-C molecules, each of
which has its own rules for peptide
binding. Therefore, recognition by
KIR can only work if the peptide does
not contribute to specificity. The ex-
tensive polymorphism of HLA class I
and the very limited repertoire of KIR
are not compatible with peptide-spe-
cific binding to HLA class I in the con-
text of diseases or infections.
In contrast, CD94 binding to the
nonpolymorphic HLA-E is governed
by peptide specificity (9). HLA-E nor-
mally binds a peptide derived from sig-
nal sequences of other HLA class I
molecules, and recognition by CD94 is
lost when HLA-E instead binds a pep-
tide derived from the signal sequence
of heat shock protein 60 (27). This
“modified self” situation could induce
the killing of cells undergoing a stress
response by NK cells that are normally
inhibited by HLA-E.
 
The strength of inhibition hypothesis
 
Several of the genetic studies have sug-
gested a model whereby inhibition of
NK cells by some KIR–HLA combina-
tions is stronger than others. In this
model, the inhibition by KIR2DL1–
HLA-C2 is strongest, followed by
KIR2DL2–HLA-C1, and finally
KIR2DL3–HLA-C1 (1, 4–6, 17). Ac-
cordingly, weaker inhibitory inter-
actions result in greater NK cell ac-
tivation and better protection from
virus infection, or greater susceptibil-
ity to autoimmunity. Similarly, in pre-
eclampsia  too strong an inhibition by
KIR2DL1–HLA-C2 interactions pre-
vents proper NK cell activation (6),
which may be required to stimulate
vascularization. The results of Car-
rington et al. (1) also support such a
 
Table II.
 
KIR molecules and their HLA ligands
 
KIR  Structure Ligand
 
K
 
d
 
 (reference) Signaling Function
 
2DL1 HLA-C2
 
Lys80
 
 
 
10 
 
 
 
M (30) ITIM Inhibition
2DS1 HLA-C2
 
Lys80
 
 (weak) DAP12 Activation
2DL2
 
a
 
HLA-C1
 
Asn80
 
 
 
10 
 
 
 
M (31) ITIM Inhibition
2DL3
 
a
 
HLA-C1
 
Asn80
 
 
 
7–9 
 
 
 
M (30, 32) ITIM Inhibition
2DS2 HLA-C1
 
Asn80
 
 (weak) DAP12 Activation
2DL4 HLA-G ? Activation
2DL5 ? ITIM Inhibition
2DS3 ? DAP12 Activation
2DS4 ? DAP12 Activation
2DS5 ? DAP12 Activation
3DL1
 
b
 
HLA-Bw4 ITIM Inhibition
3DS1
 
b
 
? DAP12 Activation
3DL2 HLA-A (weak) ITIM Inhibition
3DL3 ? ITIM Inhibition
 
, extracellular immunoglobulin domain;  , transmembrane charge;  , cytoplasmic ITIM.
 
a
 
2DL2 and 2DL3 segregate as alleles.
 
b
 
3DL1 and 3DS1 segregate as alleles.
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connection between strength of KIR-
mediated inhibition and disease out-
come. However, careful affinity mea-
surements by surface plasmon resonance
with each of the purified KIR2DL
molecules and their HLA-C ligands
have resulted in almost identical values
(Table II). On the other hand, bind-
ing of KIR2DL–Fc fusion proteins to
HLA-C followed a pattern consistent
with diminishing strength, in the order
KIR2DL1
 
 
 
KIR2DL2
 
 
 
KIR2DL3 (13).
Differences in inhibitory strength among
KIR2DLs may also be related to signal-
ing in the cytosol, and not to HLA-C
binding. An interesting feature of
KIR2DLs is a requirement for Zn
 
2
 
 
 
 in
their inhibitory function (28). Kinetic
measurements of KIR2DL binding to
HLA-C revealed slower off rates in the
presence of Zn
 
2
 
 
 
, particularly in the
case of KIR2DL1 (14). Thus, it is pos-
sible that differences in sustained en-
gagement of KIR due to Zn
 
2
 
 
 
 could
translate into differences in strength of
inhibition.
 
Concluding remarks
 
An analysis of receptor–ligand interac-
tions in the context of diseases is re-
quired to understand how HLA–KIR
genotypes contribute to disease. It will
be important to determine in what tis-
sue and with what ligand-expressing
cells are KIR-expressing NK cells and
T cells interacting. Such questions are
difficult to address, as the lack of KIR
conservation in mice precludes the use
of a convenient animal model.
Whether the published correlations
will hold up to further scrutiny remains
to be seen. A major effort is underway
to type KIR gene polymorphism and
expression in the context of KIR-mis-
matched bone marrow transplantation
(17). The same typing techniques can
be applied to refine disease associations.
Will a precise analysis of KIR alleles
and KIR expression, rather than overall
genotypes, result in stronger associa-
tions or loss of statistical significance? It
is also possible that the strong linkage
disequilibrium within the KIR gene
complex accounts for disease associa-
tions, and that a linked gene is respon-
sible for the observed effect. HLA–dis-
ease associations were first reported in
the 1970s (29), a decade before the
realization that HLA molecules bind
peptides, and two decades before the
resolution of TCR–MHC structures.
Hopefully a molecular basis for the
new disease associations with HLA–
KIR gene combinations will be pro-
vided before the year 2025.
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